If you’re holding Novo Nordisk stock or considering jumping in, you’ve probably watched its recent moves with more than a little curiosity. Novo Nordisk may not be a household name on every street, but within the investing world it turns heads, thanks to a long-term run that’s seen plenty of growth balanced by some eye-catching drops. If you’re wondering whether now is a buying opportunity, a moment to hold tight, or a signal to reconsider, you’re not alone.
Here’s what you need to know: the last year hasn’t been easy for shareholders, with the stock dipping by 53.0%. This follows a tough year-to-date return of -36.5% and a dip of -9.4% in just the past week. Yet, zoom out, and the picture changes. Novo Nordisk still boasts a 72.1% gain over five years, an impressive climb that hints at the resilience behind the recent turbulence, even with the more modest 15.8% gain over three years.
Much of this volatility has tracked broader market shifts and changing investor appetite for growth versus value. As trends in the healthcare sector and interest rates continue to evolve, risk perceptions can swing quickly, impacting companies like Novo Nordisk even when their long-term story holds up well.
But is Novo Nordisk undervalued or is there more downside risk on the horizon? Our valuation score is a confident 5 out of 6, meaning the company ticks almost every box when screened against six key undervaluation checks. With that foundation, let’s dive into the main ways analysts size up Novo Nordisk’s value. And stick around, because at the end I’ll reveal a smarter, often overlooked approach that brings even more clarity to the valuation question.
The Discounted Cash Flow (DCF) model is a well-known valuation technique that estimates a company’s intrinsic value by projecting its future cash flows and discounting them back to today’s terms. This approach provides a detailed view of what Novo Nordisk’s future performance could mean for investors in today’s money.
For Novo Nordisk, the latest twelve-month Free Cash Flow (FCF) stands at over DKK 68.4 Billion. Analyst estimates suggest that FCF could climb to approximately DKK 141.5 Billion in 2029. These projections are based on detailed analyst estimates for the coming five years, with later years extrapolated by Simply Wall St to complete a ten-year outlook.
Using the two-stage Free Cash Flow to Equity model, with all figures in Danish Krone (DKK), the model calculates a fair value of DKK 173.54 per share. The DCF indicates the stock is trading at a 68.0% discount to this estimated intrinsic value, suggesting that Novo Nordisk appears to be significantly undervalued by this measure.
Our Discounted Cash Flow (DCF) analysis suggests Novo Nordisk is undervalued by 68.0%. Track this in your watchlist or portfolio, or discover more undervalued stocks.
The Price-to-Earnings (PE) ratio is one of the most widely used valuation multiples for profitable companies like Novo Nordisk. It gives investors a snapshot of how much they are paying for each unit of earnings, making it a practical way to gauge whether shares are priced fairly relative to profits.
What counts as a “normal” or “fair” PE ratio typically depends on the company’s growth prospects and perceived risks. Companies expected to grow earnings faster, or with more stable profit streams, usually trade at higher PE multiples. In contrast, slower-growing or riskier companies have lower PEs.
Currently, Novo Nordisk trades at a PE of 13.9x. This is lower than both the pharmaceutical industry average of 18.3x and the peer average of 24.0x. However, using Simply Wall St’s proprietary “Fair Ratio” calculation, which incorporates growth forecasts, risk, profit margins, company size, and industry dynamics, the fair PE multiple for Novo Nordisk is estimated to be 32.7x. This approach provides a more tailored benchmark than simply looking at industry or peer averages, as it reflects the specific qualities and expectations unique to Novo Nordisk.
Comparing the actual PE ratio of 13.9x to the Fair Ratio of 32.7x suggests the shares are trading well below their intrinsic value. This reinforces the potential that Novo Nordisk is currently undervalued by this metric.
Earlier, we mentioned that there is an even smarter way to evaluate companies than just focusing on valuation multiples or models: introducing Narratives. A Narrative is simply your story about a company’s future—your personal view based on what you think will happen with its revenue, earnings, and profit margins, and what you believe is a fair value for the stock.
With Narratives on Simply Wall St’s Community page, you connect Novo Nordisk’s business story directly to a dynamic financial forecast and a personalized estimate of fair value. Instead of relying on a single analysis or “one-size-fits-all” price, Narratives let you factor in your unique view, whether you think Novo’s pipeline is about to deliver breakthrough growth or that persistent risks will limit returns, and see what that means in today’s numbers.
This approach helps you decide when to buy or sell by comparing your own evolving Fair Value to the live share price, making timing your decisions easier and more transparent. Narratives are also updated automatically every time important news or earnings reports are released, so your perspective stays fresh and relevant.
For example, some investors forecast Novo Nordisk’s fair value near $145, expecting strong execution and pipeline wins. More cautious users see value closer to $70, focusing on policy risks and slower growth. Both views can be tracked and tested as market conditions change.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
